ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1628

Lung Function Decline in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease in the SENSCIS Trial: Subgroup Analysis by Time Since First Non-Raynaud Symptom

Aryeh Fischer1, Oliver Distler 2, Dinesh Khanna 3, Yannick Allanore 4, Anna Maria Hoffmann-Vold 5, Gabriele Valentini 6, Toby Maher 7, Martin Aringer 8, Leslie Meng 9, Margarida Alves 10, Martina Gahlemann 11, Manuel Quaresma 10 and Masataka Kuwana 12, 1University of Colorado School of Medicine, Denver, Colorado, USA, Denver, CO, 2Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland, 3Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, 4Dept. of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, Paris, France, 5Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, 6Dipartimento di Medicina di Precisione, II Policlinico U.O. Reumatologia, Napoli, Italy, Napoli, Italy, 7National Heart and Lung Institute, Imperial College London, UK and National Institute for Health Research Clinical Research Facility, Royal Brompton Hospital, London, UK, London, United Kingdom, 8Division of Rheumatology, Department of Medicine III, University Medical Center & Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany, Dresden, Germany, 9Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, Ridgefield, 10Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, 11Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland, Basel, Switzerland, 12Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, Bunkyo-ku, Tokyo, Japan

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: autoimmune diseases, interstitial lung disease, Scleroderma, therapy and fibrosis

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 11, 2019

Session Title: Systemic Sclerosis & Related Disorders – Clinical Poster II

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Interstitial lung disease (ILD) is a common and usually early manifestation of systemic sclerosis (SSc). Decline in lung function in patients with SSc-ILD is generally believed to be most rapid early in the course of the disease. In the SENSCIS trial, nintedanib reduced the annual rate of decline in forced vital capacity (FVC) vs placebo in patients with SSc-ILD. We analyzed outcomes in the SENSCIS trial in subgroups based on time since onset of first non-Raynaud symptom.

Methods: Subjects with SSc-ILD with onset of first non-Raynaud symptom < 7 years before screening, ≥10% fibrosis of the lungs on high-resolution computed tomography (HRCT) and FVC ≥40% predicted were randomized to receive nintedanib 150 mg bid or placebo. We analyzed outcomes in subgroups based on time (at randomization) since onset of the first non-Raynaud symptom (≤3 vs >3 years).

Results: Among 576 patients who received ≥1 dose of trial drug, the time since onset of first non-Raynaud symptom was ≤3 years in 118 (40.9%) and 127 (44.1%) of patients in the nintedanib and placebo groups, respectively. At baseline, in patients with onset of first non-Raynaud symptom ≤3 years and >3 years, respectively, 41% and 60% had diffuse cutaneous SSc, 59% and 62% were positive for anti-topoisomerase I antibody, mean (SD) modified Rodnan skin score (mRSS) was 9.8 (8.8) and 12.1 (9.0), C-reactive protein level (mg/dL) was 7.1 (20.1) and 5.8 (10.7), extent of fibrosis on HRCT (%) was 34.8 (21.0) and 36.9 (21.4), FVC (mL) was 2549 (819) and 2463 (744), and FVC % predicted was 73.1 (16.1) and 72.1 (17.1). In both the nintedanib and placebo groups, the rate of decline in FVC (mL/year) was numerically greater in patients with onset of first non-Raynaud symptom ≤3 than >3 years (Figure). Nintedanib reduced the rate of decline in FVC compared with placebo both in patients with onset of first non-Raynaud symptom ≤3 and >3 years, with a similar effect between subgroups (Figure). In the nintedanib and placebo groups, respectively, absolute declines in FVC >5% predicted were seen in 21.2% and 33.1% of patients with onset of first non-Raynaud symptom ≤3 years (OR 0.55 [95% CI 0.31, 0.98) and 20.1% and 24.8% with onset >3 years (OR 0.76 [0.45, 1.28]) (treatment-by-subgroup interaction p=0.41). The adverse event profile of nintedanib was consistent between the subgroups by time since onset of first non-Raynaud symptom.  

Conclusion: In patients with SSc-ILD in the SENSCIS trial, the rate of FVC decline over 52 weeks was numerically greater in patients whose onset of first non-Raynaud symptom was ≤3 years than >3 years before randomization. The effect of nintedanib on reducing decline in FVC was consistent between subgroups of patients by time since first non-Raynaud symptom.


Disclosure: A. Fischer, Boehringer Ingelheim, 5, Bristol Myers Squibb, 5, Bristol-Myers Squibb, 5, Hoffmann-La Roche, 5, Roche, 5; O. Distler, A. Menarini, 5, Abbvie, Acceleron, 5, Acceleron Pharma, 5, Actelion, 2, 5, 8, Actelion Pharmaceuticals, 2, 5, 8, 9, Amgen, 5, AnaMar, 2, 5, Bayer, 2, 5, 8, 9, Biogen Idec, 2, 5, Blade Therapeutics, 5, Boehringer Ingelheim, 2, 5, 8, 9, Catenion, 5, 9, ChemomAb, 2, 5, ChemomAB, 5, CSL Behring, 5, Ergonex, 5, espeRare Foundation, 2, 5, Genentech/Roche, 2, 5, GlaxoSmithKline, 5, GSK, 2, 5, Holds Patent mir-29 for the treatment of systemic sclerosis, 9, Inventiva, 2, 5, iQvia, 5, Italfarmaco, 2, 5, Italfarmco, 5, Lilly, 2, 5, med, 5, 8, medac, 5, Medac, 2, 5, MedImmune, 2, 5, Medscape, 5, 8, 9, Menarini, 8, Mepha, 8, Mitsubishi Tanabe, 2, 5, Mitsubishi Tanabe Pharma, 2, 5, MSD, 5, 8, Novartis, 2, 5, 8, 9, Patent, 9, Patent issued, 9, Pfizer, 2, 5, 8, Pharmacyclics, 2, 5, Roche, 5, 8, 9, Sanofi, 2, 5, Sinoxa, 2, 5, Target Bio Science, 5, Target BioScience, 5, UCB, 2, 5, 9, UCB in the area of potential treatments of scleroderma and its complications, 2, 5; D. Khanna, Acceleron, 5, 8, Acceleron Pharma, 5, Actelion, 5, 8, Actelion Pharmaceuticals, 5, Astra Zeneca, 5, Bayer, 2, 5, 8, Behring, 5, Blade, 5, Blade Therapeutics, 5, 8, Blade therapeutics, 5, BMS, 2, 5, 8, Boehringer Ingelham, 5, Boehringer Ingelheim, 5, 8, Boehringer-Ingelheim, 5, Bristol Myers Squibb, 2, 5, Bristol-Myers Squibb, 2, 5, Celegene, 5, Celgene, 5, 8, ChemomAB, 5, ChemomAb, 5, CiviBioPharma, Inc., 3, Corbus, 5, Corobus, 5, Corpus, 5, CSL Behring, 5, 8, Curizon, 5, Curzion, 5, Cytori, 5, 8, Eicos, 4, Eicos Sciences, 4, Eicos Sciences, Inc, 4, Eicos Sciences, Inc/ CiviBioPharma, Inc, 1, 4, Eicos Sciences, Inc/ CiviBioPharma, Inc., 1, Eicos, Inc, 4, Eicos, Inc., 5, 8, Eicos, INC., 4, Galapagos, 5, Genentech, 5, Genentech/Roche, 5, GlaxoSmithKline, 5, GSK, 5, Horizon, 2, 5, Mitsubishi Tanabe Pharma, 5, Mitsubishi Tanabe Pharma Dev America, 5, Mitsubishi Tanabe Pharma Development America, 5, Mitsubishi Tanabi, 5, NIH K24 and R01, 2, NIH / NIAMS K24 AR-063120, 2, NIH/NIAMS R01& K24, 2, Pfizer, 2, 5, Sanofi, 5, Sanofi Aventis, 5, Sanofi-Aventis, 5, 8, Sanofi-Aventis/Genzyme, 5, UCB, 5, UCB Pharma, 5; Y. Allanore, Actelion, 2, 5, Alpine, 2, 5, Bayer, 2, 5, BMS, 2, 5, Boehringer Ingelheim, 2, 5, Bristol Myers Squibb, 5, Bristol-Myers Squibb, 2, 5, Genentech Roche, 2, 5, Inventiva, 2, 5, Italfarmaco, 2, 5, Sanofi, 2, 5, Servier, 2, 5; A. Hoffmann-Vold, Actelion, 5, 8, Boehringer Ingelheim, 2, 5, 8, GSK, 5, 8; G. Valentini, AbbVie, 2, 5, Abbvie, 2, 5, BMS, 2, 5, Lilly, 2, 5, Pfizer, 2, 5, Sanofi, 2, 5; T. Maher, Boehringer Ingelheim, 5, 8; M. Aringer, Abbvie, 5, 8, AbbVie, 5, 8, AstraZeneca, 5, 8, BMS, 5, 8, Boehringer Ingelheim, 5, 8, Bristol-Myers Squibb, 5, 8, Chugai, 5, 8, Hexal, 8, HEXAL, 8, Lilly, 5, 8, MSD, 5, 8, Novartis, 5, 8, Pfizer, 5, 8, Roche, 5, 8, Sanofi, 5, 8, Sanofi-Aventis, 5, 8, UCB, 8; L. Meng, Boehringer Ingelheim, 3; M. Alves, Boehringer Ingelheim, 3; M. Gahlemann, Boehringer Ingelheim, 3; M. Quaresma, Boehringer Ingelheim, 3; M. Kuwana, Abbvie, 2, 8, Actelion, 2, 8, Actelion Pharmaceuticals, 2, 8, Astellas, 2, 8, Bayer, 5, Boehringer Ingelheim, 5, Boehringer-Ingelheim, 5, Chugai, 2, 5, 8, Corbus, 5, CSL Behring, 5, CSL Berling, 5, Eisai, 2, 8, Eli Lilly, 2, Janssen, 8, Japan Blood Products Organization, 8, MBL, 7, 8, Ono, 2, 8, Pfizer, 2, Reata, 5, Tanabe-Mitsubishi, 2, 8.

To cite this abstract in AMA style:

Fischer A, Distler O, Khanna D, Allanore Y, Hoffmann-Vold A, Valentini G, Maher T, Aringer M, Meng L, Alves M, Gahlemann M, Quaresma M, Kuwana M. Lung Function Decline in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease in the SENSCIS Trial: Subgroup Analysis by Time Since First Non-Raynaud Symptom [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/lung-function-decline-in-patients-with-systemic-sclerosis-associated-interstitial-lung-disease-in-the-senscis-trial-subgroup-analysis-by-time-since-first-non-raynaud-symptom/. Accessed February 3, 2023.
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/lung-function-decline-in-patients-with-systemic-sclerosis-associated-interstitial-lung-disease-in-the-senscis-trial-subgroup-analysis-by-time-since-first-non-raynaud-symptom/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences